Skip to main content
Home » Reports » Healthcare » Blood Glucose Monitoring Devices Market
ReesrachMoz Brochure Icon

Global Blood Glucose Monitoring Devices Market Analysis and Forecast 2019-2027

Report ID:642Healthcare260 pages

Blood Glucose Monitoring Devices Market Statistics

The global blood glucose monitoring devices market is anticipated to expand at a 4.3% CAGR and may reach the estimated valuation of USD 11.99bn by 2027 as against its valuation of USD8.49bn in 2019.

Although, there is no age for diabetes and there are kinds of diabetes such as type 1, type2, gestational diabetes, etc. It is increasingly becoming necessary to take preventive measures to keep blood sugar levels in control. The chances of getting them is more in adulthood, thus preventive care measures are projected to drive the global blood glucose monitoring devices market.

Smart Self-Monitoring Devices to Drive the Market

With the advent of digitization, wireless glucose monitoring devices are becoming increasingly popular in blood sugar management. Everything is getting smarter in the age of digitalization, and so are blood glucose monitoring devices. Smart devices such as wrist bands, phones, apps, etc. are have inbuilt devices that can help in monitoring vitals such as heart rate, pulse, etc. Similarly, glucose monitoring devices can collect data based on readings and send them to the doctor with the help of sensors. Later, these data will be stored in the device as positive or false positive, based on the doctor’s validation or not. Therefore, the growing adoption of smart devices is projected to drive the global blood glucose monitoring devices market in the near future.

Global Blood Glucose Monitoring Devices Market Share By Region Type

Obesity to Boost the Sales of Blood Glucose Monitoring Devices

Obesity is a lifestyle disease and it is associated with underlying pathological issues. While obesity is more prevalent in developed nations, it is also growing in developing nations. Obesity and diabetes have a complex relationship with each other and type 2 diabetes kicks in with obesity. According to WHO’s reports, in the year 2000, the number of diabetes patients on a global level was 171million and it is likely to grow up to up to 366 million by 2030. Obesity is a precursor to type 2 diabetes, thus the risk is manyfold when obesity takes over. These factors may boost the sales of blood glucose monitoring.

Further, during the onset of covid pandemic, the blood glucose monitoring devices demand surged due to growing online health management to avoid unnecessary hospital visits and prioritize covid emergency care. The readiness to meet with such emergencies is expected to boost the demand for blood glucose monitoring devices market in the coming years.

However, lack of clear guidance on frequency in testing may hinder the growth of the global blood glucose monitoring devices market.

Nevertheless, growing awareness about the types of diabetes is projected to expand the global blood glucose monitoring market.

Data Points Market Insights
Market Value 2019 US$ 8.49billion
Market Value 2027 US$ 11.99 billion
Market Growth Rate 2020-2027 4.3%
Top Regional Market North America
Key Players Trivitron Healthcare, Medonica Co. LTD, OsteoSys Corp CyberLogic, Inc. MEDILINK ,Osteometer MediTech, CompuMed, Inc., Echolight S.p.a, Eurotec Medical Systems SRL., Hologic Inc. GE Healthcare, Beammed Ltd. DMS Imaging Swissray International, Inc. Xingaoyi Medical Equipment Co. Ltd., Eurotec Medical Systems srl, Scanflex Healthcare AB
Segment- Product Outlook (Self-monitoring Devices, Continuous Blood Glucose Monitoring Device)
End-use Outlook (Home Care, Diagnostic Centers, Hospitals)

Hypoglycaemia to Boost Self-Monitoring Segment

On the basis of product types, the global blood glucose monitoring devices market is divided into self-monitoring devices, continuous monitoring devices. However, a self-monitoring devices would take up a larger share due to the risk of developing hypoglycaemia, patients taking insulin, and tendency to develop ketosis, etc. Further, it is sub divided into glucose meters, lancets, and strips. However, the strips segment is anticipated to thrive in the market, in fact, glucose meters and strips go hand in hand. Strips are used in glucose meters to read the blood sugar levels, the strips have been packed with technology in a small space and these strips are not just affordable but also accurate with readings.

Alternatively, continuous blood glucose monitoring device is likely to witness a substantial growth in the coming years due to increase in number of type 1 diabetes. Furthermore, it is sub divided into- sensors, transmitters, receivers, and insulin pumps. Continuous blood glucose monitoring devices operate with the help of sensor which is inserted over the skin. The sensor reads the blood sugar levels and transmits the data to monitor.

Based on end users’ segment, the global blood glucose monitoring devices market is segmented into- home, clinics, and hospitals. However, the home segment is foretold to register a highest growth due growing adoption of self-management of the disease using self-monitoring devices.

North America Thrives

Based on region, North America is projected to thrive and hold a larger share in the global blood glucose monitoring devices market. The growth in the region may be primarily due to the increasing prevalence of obesity in the region. According of National Centre for Biotechnology Information, obesity in United States is a serious problem and need to be tackled with complex solutions.

Simultaneously, Asia Pacific is projected to grow during the forecast period due to rising awareness about preventive care, better health infrastructure, and patient-centric self-management.

Competitive Landscape

In Feb 2022, Abbott announced their collaborations with global health tech partners such as Sugar. Fit, BeatO, PharmEasy, Healthifime, and Fitterfly to open the doors for holistic diabetes management and extend glucose monitoring support to 8 million population that is affected with diabetes.

In March 2022, Ascensia Diabetes Care launched a new remote monitoring app Eversense®, for android users as continuous glucose monitoring system. It can collect real-time data and send it to family and friends chosen by the user. At a time, five people can receive the data of the user.

In March 2022, Novo Nordisk announced the approval of Ozempic® 2.0 mg by the FDA under diabetic treatment, in the US.

Following are the major players in the global blood glucose monitoring devices market

  • Abbott Laboratories
  • Medtronic plc
  • F. Hoffmann-La Roche Ltd.
  • Ascensia Diabetes Care
  • Insulet Corporation
  • Ypsomed Holdings
  • Glysens Incorporated
  • Dexcom, Inc.
  • Sanofi
  • Novo Nordisk

Product Outlook (Revenue, USD Billion)

  • Self-monitoring Devices
  • Testing Strips
  • Lancets
  • Blood Glucose Meter

Continuous Blood Glucose Monitoring Devices

  • Transmitter & Receiver
  • Insulin Pumps
  • Sensors

End-use Outlook (Revenue, USD Billion)

  • Home Care
  • Diagnostic Centers
  • Hospitals

Regional Outlook

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

  • What is the expected valuation of the global blood glucose monitoring device market?

The global blood glucose monitoring device market may reach the estimated valuation of USD 11.99bn by 2027

  • Which end-use segment would account a larger share of the global blood glucose monitoring device market?

Home segment is projected to account for a larger share of the global blood glucose monitoring device market

  • What are restraints in the blood glucose monitoring device market?

Short falls in the clear guidance on frequency in testing might hamper the blood glucose monitoring device market

  • Who are the major players in the global blood glucose monitoring device market?

Insulet Corporation, Ypsomed Holdings, Glysens Incorporated, Dexcom, Inc., Sanofi, Novo Nordisk, Abbott Laboratories, Medtronic plc,F. Hoffmann-La Roche Ltd., Ascensia Diabetes Care.

Table Of Content

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations

2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics

4. Global Blood Glucose Monitoring Devices Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis

5. Global Blood Glucose Monitoring Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Product Outlook
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Product Outlook, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Product Outlook, 2022-2032
5.3.1. Self-monitoring Devices
5.3.1.1. Testing Strips
5.3.1.2. Lancets
5.3.1.3. Blood Glucose Meter
5.3.2. Continuous Blood Glucose Monitoring Devices
5.3.2.1. Transmitter & Receiver
5.3.2.3. Insulin Pumps
5.3.2.3. Sensors
5.4. Y-o-Y Growth Trend Analysis By Product Outlook, 2017-2021
5.5. Absolute $ Opportunity Analysis By Product Outlook, 2022-2032

6. Global Blood Glucose Monitoring Devices Market Analysis 2017-2021 and Forecast 2022-2032, By End-use Outlook
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By End-use Outlook, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By End-use Outlook, 2022-2032
6.3.1. Home Care
6.3.2. Diagnostic Centers
6.3.3. Hospitals
6.4. Y-o-Y Growth Trend Analysis By End-use Outlook, 2017-2021
6.5. Absolute $ Opportunity Analysis By End-use Outlook, 2022-2032

7. Global Blood Glucose Monitoring Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region

8. North America Blood Glucose Monitoring Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Product Outlook
8.2.3. By End-use Outlook
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Product Outlook
8.3.3. By End-use Outlook
8.4. Key Takeaways

9. Latin America Blood Glucose Monitoring Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Argentina
9.2.1.4. Chile
9.2.1.5. Peru
9.2.1.6. Rest of Latin America
9.2.2. By Product Outlook
9.2.3. By End-use Outlook
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Outlook
9.3.3. By End-use Outlook
9.4. Key Takeaways

10. Europe Blood Glucose Monitoring Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. Italy
10.2.1.3. France
10.2.1.4. U.K.
10.2.1.5. Spain
10.2.1.6. Russia
10.2.1.7. BENELUX
10.2.1.8. Rest of Europe
10.2.2. By Product Outlook
10.2.3. By End-use Outlook
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Outlook
10.3.3. By End-use Outlook
10.4. Key Takeaways

11. East Asia Blood Glucose Monitoring Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By Product Outlook
11.2.3. By End-use Outlook
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Outlook
11.3.3. By End-use Outlook
11.4. Key Takeaways

12. South Asia Blood Glucose Monitoring Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Malaysia
12.2.1.4. Indonesia
12.2.1.5. Rest of South Asia
12.2.2. By Product Outlook
12.2.3. By End-use Outlook
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Outlook
12.3.3. By End-use Outlook
12.4. Key Takeaways

13. Oceania Blood Glucose Monitoring Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Product Outlook
13.2.3. By End-use Outlook
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Outlook
13.3.3. By End-use Outlook
13.4. Key Takeaways

14. MEA Blood Glucose Monitoring Devices Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC
14.2.1.2. Rest of MEA
14.2.2. By Product Outlook
14.2.3. By End-use Outlook
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Outlook
14.3.3. By End-use Outlook
14.4. Key Takeaways

15. Key Countries Blood Glucose Monitoring Devices Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Product Outlook
15.1.2.2. By End-use Outlook
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Product Outlook
15.2.2.2. By End-use Outlook
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Product Outlook
15.3.2.2. By End-use Outlook
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Product Outlook
15.4.2.2. By End-use Outlook
15.5. Argentina
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Product Outlook
15.5.2.2. By End-use Outlook

16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1.  By Regional
16.3.2.  By Product Outlook
16.3.3.  By End-use Outlook

17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Abbott Laboratories
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Medtronic plc
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. F. Hoffmann-La Roche Ltd.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Ascensia Diabetes Care
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Insulet Corporation
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Ypsomed Holdings
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Glysens Incorporated
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Dexcom, Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Sanofi
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
17.1.10. Novo Nordisk
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments (Product/Age /Sales Channel/Region)
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.10.5.2. Product Strategy
17.1.10.5.3. Channel Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Request Free Sample

Hidden
Company logos Strips